Health&Life Co

Health&Life Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Health&Life Co (1781.TWO) as of Oct 26, 2026 is -37.92. In the previous year, Net Debt to Free Cash Flow Ratio was 6.25 — a change of -707.07% (lower).

Net Debt/FCF

-37.92

YoY

-707.07%

Last updated:

Net Debt to Free Cash Flow Ratio of Health&Life Co is 2025 -37.92 . Net Debt to Free Cash Flow Ratio of Health&Life Co was 2024 6.25 . It decreases by -707.07% lower compared to the previous year.

The Health&Life Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
0.76 TWD
Jan 1, 2019
0.25 TWD
Jan 1, 2020
3.21 TWD
Jan 1, 2021
-0.30 TWD
Jan 1, 2022
-0.34 TWD
Jan 1, 2023
0.25 TWD
Jan 1, 2024
6.25 TWD
Jan 1, 2025
-37.92 TWD
The Health&Life Co Net Debt/FCF history
YEARNet Debt/FCFYoY
-37.92-707.07%
6.25+2,396.54%
0.25-173.81%
-0.34+11.38%
-0.30-109.47%
3.21+1,163.25%
0.25-66.73%
0.76-104.86%
-15.72-803.88%
2.23-120.55%
-10.87-849.28%
1.45—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Health&Life Co Stock analysis

What does Health&Life Co do? Health&Life Co Ltd generates revenue through the manufacturing and distribution of cardiovascular disease, in-vitro diagnostics, and respiratory care products. The company's primary products include electronic sphygmomanometers such as blood pressure monitors, nebulizers, and blood glucose monitoring systems, which measure and record systolic and diastolic blood pressure and glucose levels. These products are sold domestically in Taiwan and internationally to overseas markets. The firm targets healthcare providers, clinics, and consumers seeking home health monitoring solutions for chronic conditions like hypertension and diabetes. The company's product portfolio focuses on electronic sphygmomanometers, which are essential for daily health monitoring. By offering devices that measure blood pressure and glucose levels, Health&Life Co Ltd caters to patients managing cardiovascular and metabolic diseases. The domestic market in Taiwan serves as a key sales channel, while overseas markets provide additional growth opportunities for the firm's diagnostic and respiratory care products. Health&Life Co Ltd's business model relies on direct sales of medical devices to healthcare institutions and end-users. The firm's electronic sphygmomanometers, including blood pressure monitors and blood glucose systems, are distributed through both domestic and international channels. This approach ensures consistent revenue streams from the ongoing demand for home health monitoring equipment among patients with chronic conditions. Health&Life Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Health&Life Co stock

Net Debt to Free Cash Flow Ratio of Health&Life Co is -37.92 in 2025.

Net Debt to Free Cash Flow Ratio of Health&Life Co changed from 6.25 to -37.92, representing a -707.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Health&Life Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Health&Life Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Health&Life Co

All Key Metrics — Health&Life Co